CA2638866C - Peptide based inhibition of capcna protein-protein interactions in cancer - Google Patents

Peptide based inhibition of capcna protein-protein interactions in cancer Download PDF

Info

Publication number
CA2638866C
CA2638866C CA2638866A CA2638866A CA2638866C CA 2638866 C CA2638866 C CA 2638866C CA 2638866 A CA2638866 A CA 2638866A CA 2638866 A CA2638866 A CA 2638866A CA 2638866 C CA2638866 C CA 2638866C
Authority
CA
Canada
Prior art keywords
capcna
peptide
protein
pcna
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2638866A
Other languages
English (en)
French (fr)
Other versions
CA2638866A1 (en
Inventor
Robert J. Hickey
Linda H. Malkas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CA2638866A1 publication Critical patent/CA2638866A1/en
Application granted granted Critical
Publication of CA2638866C publication Critical patent/CA2638866C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2638866A 2006-02-17 2007-02-16 Peptide based inhibition of capcna protein-protein interactions in cancer Active CA2638866C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74331306P 2006-02-17 2006-02-17
US60/743,313 2006-02-17
PCT/US2007/062335 WO2007098415A2 (en) 2006-02-17 2007-02-16 Peptide based inhibition of capcna protein-protein interactions in cancer

Publications (2)

Publication Number Publication Date
CA2638866A1 CA2638866A1 (en) 2007-08-30
CA2638866C true CA2638866C (en) 2015-11-10

Family

ID=38235155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2638866A Active CA2638866C (en) 2006-02-17 2007-02-16 Peptide based inhibition of capcna protein-protein interactions in cancer

Country Status (9)

Country Link
US (3) US8653039B2 (cg-RX-API-DMAC7.html)
EP (1) EP1989225A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009527498A (cg-RX-API-DMAC7.html)
CN (1) CN101384618A (cg-RX-API-DMAC7.html)
AU (1) AU2007217037A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0707948A2 (cg-RX-API-DMAC7.html)
CA (1) CA2638866C (cg-RX-API-DMAC7.html)
EA (1) EA200801847A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007098415A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801847A1 (ru) * 2006-02-17 2009-02-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ
WO2008036929A2 (en) * 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Complex for transferring an anionic substance into a cell
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
CA2732737C (en) * 2008-07-24 2019-03-05 Indiana University Research And Technology Corporation Cancer peptide therapeutics
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
WO2011044374A1 (en) * 2009-10-07 2011-04-14 Indiana University Research And Technology Corporation Capcna peptide therapeutics for cancer
EP2538959A1 (en) * 2010-02-24 2013-01-02 Institut National de la Santé et de la Recherche Médicale Compounds for the treatment of inflammation and neutropenia
JP2013522613A (ja) * 2010-03-18 2013-06-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 化学療法に対する応答性を予測するための方法
US9475840B2 (en) 2012-02-27 2016-10-25 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US10420840B2 (en) * 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
JP2020514256A (ja) * 2016-12-15 2020-05-21 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ,リミテッド 抗pcnaモノクローナル抗体及びその使用
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935797A (en) 1994-06-16 1999-08-10 Stanford University Interaction of MHC Class II proteins with members of the PCNA family of proteins
GB9509557D0 (en) * 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
JP2002518341A (ja) * 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
US7294471B2 (en) 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
MX2007013584A (es) 2005-04-27 2008-04-22 Univ Indiana Res & Tech Corp Anticuerpos de isoforma de cspcna y sus usos.
DE602006021178D1 (de) 2005-06-27 2011-05-19 Univ Indiana Res & Tech Corp Cspcna-isoform-modifikationen und anwendungen davon
EA200801847A1 (ru) * 2006-02-17 2009-02-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ

Also Published As

Publication number Publication date
US9187526B2 (en) 2015-11-17
EP1989225A2 (en) 2008-11-12
CN101384618A (zh) 2009-03-11
BRPI0707948A2 (pt) 2011-05-17
US20140296156A1 (en) 2014-10-02
US20090232882A1 (en) 2009-09-17
CA2638866A1 (en) 2007-08-30
US20160304559A1 (en) 2016-10-20
WO2007098415A3 (en) 2007-12-13
US8653039B2 (en) 2014-02-18
AU2007217037A1 (en) 2007-08-30
WO2007098415A2 (en) 2007-08-30
JP2009527498A (ja) 2009-07-30
EA200801847A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
US8653039B2 (en) Peptide based inhibition of caPCNA interaction in cancer
US10188699B2 (en) CAPCNA peptide therapeutics for cancer
KR101653774B1 (ko) 올리고펩타이드 화합물 및 이의 용도
CA2732737C (en) Cancer peptide therapeutics
Machida et al. A novel adenine nucleotide translocase inhibitor, MT-21, induces cytochrome c release by a mitochondrial permeability transition-independent mechanism
JP6408555B2 (ja) 融合タンパク質及びブロモドメイン阻害化合物の識別方法
CA2575123A1 (en) Peptide sequence for modulation of delta protein kinase c
US9593148B2 (en) DPP8 and DPP9 peptide inhibitors
Bendzunas All Hydrocarbon Stapled Peptides as Allosteric Modulators of Protein-Protein Interactions
KR20250047483A (ko) Braf 활성 억제 단백질 및 이를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
EP2429563B1 (en) Peptide able to disrupt the protein complex between the his273 mutated p53 protein and the oncosuppressive p73 protein in tumour cells and therapeutic uses thereof
EP2578227B1 (en) Cancer therapy method
Merwin A C-terminus mitochondrial-localization region and BH3 Domain of Puma are required for apoptotic function
Teichmann et al. Modulation of SHP‐1 phosphatase activity by monovalent and bivalent SH2 phosphopeptide ligands
HK1214177B (en) Cancer peptide therapeutics

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207